Acute GVHD (aGvHD) remains a major complication of allo-SCT. The pathogenesis of aGvHD is related to damage to the gut epithelium (caused largely by cytotoxic conditioning), which results in host APC activation, followed by donor T-cell allo-activation and tissue injury. 1 Lack of a sensitive predictor for aGvHD has precluded individualized GvHD prophylaxis. We attempted to develop a novel imaging-based risk prediction model based on the extent of intestinal damage identified on early post-transplant computed tomography (CT).
Twenty consecutive patients with hematological malignancies who underwent allo-SCT were prospectively enrolled (#NCT02117115, June-October 2014; Table 1 ). Patients 460 years old, those with known allergy to iodinated contrast material or creatinine clearance o60 ml/min were excluded. One standard abdominopelvic computed tomography (CT) scan was performed between days +7 and +14, using a biphasic contrast protocol in the mucosal and enteric phases. The preference for doing the CT during the period between days +7 and +14 post SCT was according to the previous data suggesting maximal gut damage about 2 weeks after initiation of conditioning. 2, 3 The specific day chosen for the CT was based on logistical factors. CT scoring was based on six characteristics: vasa recta engorgement (yes: 1, no: 0), gallbladder fossa edema (yes: 1, no: 0), mesenteric edema (yes: 1, no: 0), gallbladder/biliary enhancement (none: 0, mild: 1, moderate: 2, severe: 3), bowel wall thickening/enhancement (none: 0, mild: 1, moderate: 2, severe: 3) and number of involved bowel loops (none: 0, one loop: 1, two loops: 2, three or more loops: 3). These characteristics were adopted from the radiology literature in various settings of bowel inflammation (enteritis and/ or colitis) such as with chemotherapy, 4 radiotherapy, 5 infections, 6 neutropenia 7 and Crohn's disease. 8 For grading of small bowel wall thickening, normal, mild, moderate and severe were defined as o 2 mm, 2-3 mm, 3-5 mm and 45 mm, respectively. Acceptable colon wall thickness on CT depends on the degree of bowel distension. 9 For grading of wall thickening in underdistended colon (o 1.5 cm), normal, mild, moderate and severe were defined as o 5 mm, 5-7 mm, 7-10 mm and 410 mm, respectively. For distended colon (41.5 cm), grading was similar to the small bowel as described above. GvHD was diagnosed and graded according to the IBMTR criteria. 10 All scans were reviewed on the day of CT by MFL, who remained blinded to clinical findings. All clinicians remained blinded to the CT score.
The receiver operating characteristic curve method was used to identify the optimal cutoff point for the total CT score that yielded maximum classification accuracy for the prediction of subsequent grade C-D (vs none or A-B) aGvHD. Potential redundancies in the scoring system were assessed by sequential removal of each CT feature using a backward elimination platform and re-evaluating sensitivity, specificity and classification accuracy of the scoring scheme. The simplest model with optimal performance was chosen as the final model. All statistical tests were two-sided and Po 0.05 was considered as significant.
Supplementary Tables S1 and S2 provide further details about clinical and imaging findings and outcomes. The median (range) age of patients was 52 (33-60) years, 60% were male and 90% were Caucasian. The most common diagnoses were AML (55%) and diffuse large B-cell lymphoma (15%). The disease status before transplant was CR in 60% of patients and active disease in the remainder. The donor was a matched unrelated donor (single antigen mismatch in three cases) in 65% of the transplants and a matched sibling in the remainder. The donor-recipient sex was male-male in 50%, male-female in 30%, female-female in 10% and female-male in 10% of transplants. Conditioning was myeloablative in 70% of patients and reduced intensity in the remainder. Conditioning was radiation based in 50% of patients (including one with TLI). In vivo T-cell depletion using antithymocyte globulin was performed in 15% of patients and all GvHD prophylactic regimens were calcineurin inhibitor based. Post-transplantation cyclophosphamide was used in one patient. The median (range) CD3 + T-cell dose in the infused stem cell product was 17.6 (0.9-48.9) × 10 7 /kg. A total of 16 (80%) patients developed aGvHD (grade A: 5%, grade B: 55%, grade C: 10% and grade D: 10%). There were five deaths during the first 180 days post transplant, three due to relapse and two due to severe intestinal aGvHD. Contrast nephropathy did not occur in any patient. CT scans were done on days 7-9 in 90% of patients. Eight patients had diarrhea or clinical evidence of mucositis on the day of CT, five due to conditioning toxicity and three due to Clostridium difficile infection. At the time of discharge, mucositis and diarrhea had completely resolved in all patients.
On receiver operating characteristic curve analysis, the optimal cutoff for the total CT score that yielded maximum predictive accuracy for the occurrence of grade C-D aGvHD (overall) was 5, with a sensitivity, specificity and classification accuracy of 100, 81 and 85%, respectively. Next, we sequentially removed each CT feature from the model and evaluated whether simpler models would yield equal or superior predictive performance. The simplest model with the best performance for the prediction of grade C-D aGvHD (overall) was using only two CT features: mesenteric edema (1 vs 0) and the number of involved bowel loops (0 if 0-2 loops and 1 if ⩾ 3 loops). Using a total CT score of 2 (high risk) vs 0-1 (low risk), the model had a sensitivity of 75% and a specificity of 94% to predict grade C-D aGvHD (overall), and correctly classified 90% of patients (area under the curve 0.81). These numbers did not change when we applied the model to predict any-organ stage III-IV (vs 0-II) aGvHD. Finally, the sensitivity, specificity and classification accuracy of the model for gut aGvHD stage III-IV (vs 0-II) was 100, 89, and 90%, respectively. Patients with mesenteric edema had significantly lower levels of serum albumin on the day of CT compared with those without mesenteric edema (median (range) of 3.9 (3.1-4.5) mg/dL in patients without mesenteric edema vs 3.6 (3.2-3.9) mg/dL in those with mesenteric edema; P = 0.042 on a Mann-Whitney test).
Previous work on risk factor identification during the first 2 weeks post transplantation has been limited. Goldberg et al. 11 demonstrated a significant correlation between diarrhea on days +4 to +7 and grade II-IV aGvHD. Liu et al. 12 showed that a mean volume of conditioning-related diarrhea for days − 3 to 0 larger than 7.94 ml/kg was an independent risk factor for the development of grade II-IV aGVHD. Johansson et al. 13 showed that higher intestinal absorption of 51 Cr-EDTA in the first 2 weeks following transplant predicted the development of grade II-IV aGvHD. We hypothesize that the early post-transplant period, when intestinal barrier damage is maximal and before aGvHD has developed, is a critical window during which high-risk features on abdominopelvic imaging are associated with the risk of subsequent aGvHD development. Both of our patients who succumbed to aGvHD (more than 2 months after transplant) were identified as high risk as early as 7 days post transplant (Figure 1 ). Pre-emptive escalation of immunosuppression in high-risk patients may prevent or attenuate the development of aGvHD. Imaging-based models may be combined with biomarkers to provide a more accurate risk stratification scheme for aGvHD. [14] [15] [16] Low levels of serum albumin have been shown in previous studies to correlate with regimen-related toxicity and predict higher transplant-related mortality. 3, 17 The correlation between low albumin and mesenteric edema in our study may be explained by one or both of the following mechanisms: (i) direct effect of low albumin causing fluid extravasation and (ii) intestinal barrier damage causing both mesenteric inflammation/edema and protein losing enteropathy. Also, albumin is a 'negative acute-phase protein', thus low albumin levels may reflect the acute inflammation (that is, intestinal mucositis) that causes mesenteric edema. 3 Lack of the typical imaging findings of hypoalbuminemic states (for example, subcutaneous edema and third space effusions) in our patients Figure 1 . CT and pathologic findings in a patient with fatal grade D aGvHD. This 53-year-old man with chronic myelomonocytic leukemia underwent allo-SCT using a radiation-free myeloablative conditioning regimen. His CT scan on day +9 showed mesenteric edema and bowel wall thickening in multiple bowel loops (a). His early post-transplant course following discharge from the hospital was uneventful. He presented on day +64 with rapid-onset profuse diarrhea, generalized skin rash and liver function abnormalities, consistent with severe multiorgan aGvHD. Colonoscopic findings were confirmatory. Pathological examination of a biopsy specimen demonstrated crypt destruction (b). His aGvHD was refractory to steroids, and he died a few days after presentation with grade D aGvHD (stage III skin, stage IV gut and stage IV liver). CT findings on day +9 preceded the occurrence of severe aGvHD by 55 days. 
Abbreviations: AA = African American; ATG = anti-thymocyte globulin; C = Caucasian; CMML = chronic myelomonocytic leukemia; DLBCL = diffuse large B-cell lymphoma; F = female; H = Hispanic; M = male; MA = myeloablative; MDS = myelodysplastic syndrome; MRD = matched related donor; MUD = matched unrelated donor; PCL = plasma cell leukemia; PT-Cy = post-transplant cyclophosphamide (50 mg/kg on days +3 and +4); RI = reduced intensity.
Letter to the Editor as well as the localized nature of mesenteric edema in the vicinity of the inflamed bowel loops argue against a significant direct role of albumin in the development of mesenteric edema. Our study has several strengths. First, the proposed model is the first imaging-based risk stratification system to predict subsequent aGvHD several weeks in advance. Second, it represents the first promising application of imaging in the early post-transplant period, hinting at a unique niche where the field of radiology may contribute to improving transplant outcomes. Third, we had the advantage of implementing the study in a prospective setting and in a double-blinded manner, where the clinicians were not aware of the CT scores and the radiologist did not have access to clinical information. Fourth, the method used for risk prediction is relatively inexpensive, readily available and easy to implement in real-world clinical practice. Finally, our model does not depend on the specific cause of mucositis and is not limited to a particular subset of possible etiologies for intestinal barrier damage. The mere presence of the two high-risk features in the final model, irrespective of the cause, enables the model to alarm for the high risk of subsequent severe aGvHD.
Although an accurate model from a sample of only 20 patients is promising, our results should be validated in a larger cohort where inter-observer variability in CT interpretation can be assessed. Additionally, the validity of our results in older patients needs to be evaluated in future studies. Finally, given the potential gut toxicity of post-transplant cyclophosphamide (used in one patient in this study), excluding such patients may enhance the performance of the model by making the study population more homogenous.
